<DOC>
	<DOCNO>NCT00720304</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving erlotinib together docetaxel radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well erlotinib give together docetaxel radiation therapy work treat patient stage III stage IV squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Erlotinib , Docetaxel , Radiation Therapy Stage III Stage IV Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression patient locally advance squamous cell carcinoma head neck treat erlotinib hydrochloride combination docetaxel radiotherapy . Secondary - Determine objective response rate , locoregional control rate , duration response , pattern failure , overall survival patient treat regimen . - Determine toxicity regimen patient . - Determine dose effect treatment biologic correlate tumor tissue and/or surround mucosa . OUTLINE : This multicenter study . Patients receive oral erlotinib hydrochloride daily 2 year absence disease progression unacceptable toxicity . Beginning week 3 , patient receive docetaxel IV 1 hour week radiotherapy ( may intensity-modulated ) daily 8 week absence disease progression unacceptable toxicity . At 6-8 week completion chemoradiotherapy , patient N2 great cervical lymph node involvement baseline residual disease may undergo surgery . Patients persistent disease study therapy undergo salvage surgery 6-12 week completion chemoradiotherapy . Patients undergo blood sample , tissue biopsy , mucosal scraping , saliva collection baseline periodically study . Samples analyze marker angiogenic activity ( VEGF , sVEGFR-2 , sKIT , ICAM , PDGF ) , pharmacokinetic study , gene expression profile , human papilloma virus DNA enzyme link immunosorbent assay ( ELISA ) , immunohistochemistry , fluorescence situ hybridization ( FISH ) , PCR . After completion study therapy , patient evaluate every 4-8 week 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month 2 year , year thereafter .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced squamous cell carcinoma head neck Stage III IV disease No distant metastatic disease Measurable disease ( accord RECIST ) No salivary gland paranasal sinus squamous cell carcinoma No known brain metastasis direct cerebral invasion tumor Intracranial extension ( without cerebral involvement ) may allow PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥10 g/dL Total bilirubin normal Alkaline phosphatase AND AST ALT meeting follow criterion : Alkaline phosphatase normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 5 time ULN AND AST ALT normal Creatinine normal OR creatinine clearance ≥ 60 mL/min No clinically significant heart disease include follow : NYHA class III IV heart disease Significant arrhythmias require medication Symptomatic coronary artery disease Myocardial infarction within previous six month Second thirddegree heart block bundlebranch block Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month completion study therapy No history allergic reaction attribute compound similar chemical biologic composition erlotinib hydrochloride docetaxel , include drug formulate polysorbate 80 No preexist peripheral neuropathy ≥ grade 2 No uncontrolled concurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would preclude compliance study requirement No HIV positivity No prior malignancy except follow : Squamous cell basal cell carcinoma skin Carcinoma situ cervix Cancer treat 5 year ago patient remain diseasefree Not poorly compliant PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , investigational antitumor drug No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>